131 related articles for article (PubMed ID: 11526452)
21. A conserved region of the herpes simplex virus type 1 tegument protein VP22 facilitates interaction with the cytoplasmic tail of glycoprotein E (gE).
O'Regan KJ; Bucks MA; Murphy MA; Wills JW; Courtney RJ
Virology; 2007 Feb; 358(1):192-200. PubMed ID: 16997344
[TBL] [Abstract][Full Text] [Related]
22. Efficient secretion of the herpes simplex virus tegument protein VP22 from living mammalian cells.
Mori T; Mineta Y; Aoyama Y; Sera T
Arch Virol; 2008; 153(6):1191-5. PubMed ID: 18463782
[TBL] [Abstract][Full Text] [Related]
23. Intercellular trafficking and enhanced in vivo antitumour activity of a non-virally delivered P27-VP22 fusion protein.
Zavaglia D; Favrot MC; Eymin B; Tenaud C; Coll JL
Gene Ther; 2003 Feb; 10(4):314-25. PubMed ID: 12595890
[TBL] [Abstract][Full Text] [Related]
24. Evidence for intercellular trafficking of VP22 in living cells.
Lemken ML; Wolf C; Wybranietz WA; Schmidt U; Smirnow I; Bühring HJ; Mack AF; Lauer UM; Bitzer M
Mol Ther; 2007 Feb; 15(2):310-9. PubMed ID: 17235309
[TBL] [Abstract][Full Text] [Related]
25. VP22 enhances antibody responses from DNA vaccines but not by intercellular spread.
Perkins SD; Hartley MG; Lukaszewski RA; Phillpotts RJ; Stevenson FK; Bennett AM
Vaccine; 2005 Mar; 23(16):1931-40. PubMed ID: 15734065
[TBL] [Abstract][Full Text] [Related]
26. Phosphorylation of the herpes simplex virus type 1 tegument protein VP22.
Elliott G; O'Reilly D; O'Hare P
Virology; 1996 Dec; 226(1):140-5. PubMed ID: 8941333
[TBL] [Abstract][Full Text] [Related]
27. Marek's disease virus VP22: subcellular localization and characterization of carboxyl terminal deletion Mutations.
O'Donnell LA; Clemmer JA; Czymmek K; Schmidt CJ
Virology; 2002 Jan; 292(2):235-40. PubMed ID: 11878926
[TBL] [Abstract][Full Text] [Related]
28. Deletion of the herpes simplex virus VP22-encoding gene (UL49) alters the expression, localization, and virion incorporation of ICP0.
Elliott G; Hafezi W; Whiteley A; Bernard E
J Virol; 2005 Aug; 79(15):9735-45. PubMed ID: 16014935
[TBL] [Abstract][Full Text] [Related]
29. Membrane association of VP22, a herpes simplex virus type 1 tegument protein.
Brignati MJ; Loomis JS; Wills JW; Courtney RJ
J Virol; 2003 Apr; 77(8):4888-98. PubMed ID: 12663795
[TBL] [Abstract][Full Text] [Related]
30. Fluorescent tagging of herpes simplex virus tegument protein VP13/14 in virus infection.
Donnelly M; Elliott G
J Virol; 2001 Mar; 75(6):2575-83. PubMed ID: 11222680
[TBL] [Abstract][Full Text] [Related]
31. [Anti-tumor effect of lentivirus-mediated MUCI antibody-targeted gene therapy with VP22-TK system on MUC1(+) human ovarian cancer transplanted intraperitoneally in nude mice].
Kong B; Wang W; Liu C; Ma D; Qu X; Jiang J; Yang X; Zhang Y; Jiang S
Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(17):1207-10. PubMed ID: 12475412
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of the herpes simplex virus type 1 tegument protein VP22 increases its incorporation into virus particles.
Leslie J; Rixon FJ; McLauchlan J
Virology; 1996 Jun; 220(1):60-8. PubMed ID: 8659129
[TBL] [Abstract][Full Text] [Related]
33. Intracellular trafficking of VP22 in bovine herpesvirus-1 infected cells.
Lobanov VA; Zheng C; Babiuk LA; van Drunen Littel-van den Hurk S
Virology; 2010 Jan; 396(2):189-202. PubMed ID: 19922972
[TBL] [Abstract][Full Text] [Related]
34. MDV-1 VP22: a transporter that can selectively deliver proteins into cells.
Zhang C; Qin A; Chen H; Deng X; Su Y; Qian K
Arch Virol; 2009; 154(7):1027-34. PubMed ID: 19495935
[TBL] [Abstract][Full Text] [Related]
35. Herpes simplex virus tegument protein VP22 contains an internal VP16 interaction domain and a C-terminal domain that are both required for VP22 assembly into the virus particle.
Hafezi W; Bernard E; Cook R; Elliott G
J Virol; 2005 Oct; 79(20):13082-93. PubMed ID: 16189010
[TBL] [Abstract][Full Text] [Related]
36. Efficient translocation and apoptosis induction by adenovirus encoded VP22-p53 fusion protein in human tumor cells in vitro.
Roy I; Holle L; Song W; Holle E; Wagner T; Yu X
Anticancer Res; 2002; 22(6A):3185-9. PubMed ID: 12530063
[TBL] [Abstract][Full Text] [Related]
37. HIV-1 TAT protein transduction domain mediates enhancement of enzyme prodrug cancer gene therapy in vitro: a study with TAT-TK-GFP triple fusion construct.
Meriläinen O; Hakkarainen T; Wahlfors T; Pellinen R; Wahlfors J
Int J Oncol; 2005 Jul; 27(1):203-8. PubMed ID: 15942661
[TBL] [Abstract][Full Text] [Related]
38. Fusion of herpes simplex virus thymidine kinase to VP22 does not result in intercellular trafficking of the protein.
Beerens AM; Rots MG; de Vries EF; Haisma HJ
Int J Mol Med; 2007 May; 19(5):841-9. PubMed ID: 17390091
[TBL] [Abstract][Full Text] [Related]
39. Fusion of HSV-1 VP22 to a bifunctional chimeric SuperCD suicide gene compensates for low suicide gene transduction efficiencies.
Lemken ML; Graepler F; Wolf C; Wybranietz WA; Smirnow I; Schmidt U; Gregor M; Bitzer M; Lauer UM
Int J Oncol; 2007 May; 30(5):1153-61. PubMed ID: 17390017
[TBL] [Abstract][Full Text] [Related]
40. Exploitation of the Herpes simplex virus translocating protein VP22 to carry influenza virus proteins into cells for studies of apoptosis: direct confirmation that neuraminidase induces apoptosis and indications that other proteins may have a role.
Morris SJ; Smith H; Sweet C
Arch Virol; 2002 May; 147(5):961-79. PubMed ID: 12021867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
